1. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial 
Muzaffar H. Qazilbash, Rima M. Saliba, Yago Nieto, Gaurav Parikh, Matteo Pelosini, Fatima B. Khan, Roy B. Jones, Chitra Hosing, Floralyn Mendoza, Donna M. Weber, Michael Wang, Uday Popat, Amin Alousi, Paolo Anderlini, Richard E. Champlin, Sergio Giralt, MD 
Biology of Blood and Marrow Transplantation 
Volume 14, Issue 12, Pages (December 2008)
DOI: /j.bbmt
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Kaplan-Meier estimates for OS and PFS probability for all 48 patients treated on the protocol.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) Kaplan-Meier estimates for OS probability according to randomization to 3 treatment arms (arm 1 = no ATO, arm 2 = ATO 0.15 mg/kg, arm 3 = ATO 0.25 mg/kg). (B) Kaplan-Meier estimates for PFS probability according to randomization to 3 treatment arms (arm 1 = no ATO, arm 2 = ATO 0.15 mg/kg, arm 3 = ATO 0.25 mg/kg).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Impact of ATO dose on melphalan AUC on the days of melphalan administration. AUC = area under the curve; DL1 = dose level 1/no ATO; DL2 = dose level 2/ATO 0.15 mg/kg; DL3 = dose level 3/ATO 0.25 mg/kg.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions